Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage

Experimental Neurology

Volumn 249, Issue , 2013, Pages 39-48

  Adzemovic, Milena Z ^a   Zeitelhofer, Manuel ^a   Hochmeister, Sonja ^a,b   Gustafsson, Sven A ^a   Jagodic, Maja ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Developmental stages; EAE; Multiple sclerosis; T cell response; Vitamin D supplementation

Indexed keywords

25 HYDROXYVITAMIN D; GAMMA INTERFERON; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; VITAMIN D;

ADULT ANIMAL; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DEVELOPMENTAL STAGE; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEMALE; INTERFERON PRODUCTION; JUVENILE ANIMAL; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; VITAMIN SUPPLEMENTATION;

DEVELOPMENTAL STAGES; EAE; MULTIPLE SCLEROSIS; T CELL RESPONSE; VITAMIN D SUPPLEMENTATION;

AGING; ANIMALS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION; MULTIPLE SCLEROSIS; RATS; TREATMENT OUTCOME; VITAMIN D;

EID: 84884157231     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.08.002     Document Type: Article

References (64)

1. Adzemovic M.Z., Ockinger J., Zeitelhofer M., Hochmeister S., Beyeen A.D., Paulson A., Gillett A., Thessen Hedreul M., Covacu R., Lassmann H., Olsson T., Jagodic M. Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats. PLoS One 2012, 7:e39794.
2. Amor S., Groome N., Linington C., Morris M.M., Dornmair K., Gardinier M.V., Matthieu J.M., Baker D. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J. Immunol. 1994, 153:4349-4356.
3. Archelos J.J., Storch M.K., Hartung H.P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 2000, 47:694-706.
4. Ascherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol. 2010, 9:599-612.
5. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., de Waal-Malefyt R., Coffman R.L., Hawrylowicz C.M., O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002, 195:603-616.
6. Bhalla A.K., Amento E.P., Krane S.M. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell. Immunol. 1986, 98:311-322.
7. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 2001, 167:4974-4980.
8. Bradl M., Bauer J., Flugel A., Wekerle H., Lassmann H. Complementary contribution of CD4 and CD8 T lymphocytes to T-cell infiltration of the intact and the degenerative spinal cord. Am. J. Pathol. 2005, 166:1441-1450.
9. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R., Gagne D., D'Souza C., Ursell M., O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-1859.
10. Chang J.H., Cha H.R., Lee D.S., Seo K.Y., Kweon M.N. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One 2010, 5:e12925.
11. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., Meunier P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 1997, 7:439-443.
12. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
13. Dalmay F., Bhalla D., Nicoletti A., Cabrera-Gomez J.A., Cabre P., Ruiz F., Druet-Cabanac M., Dumas M., Preux P.M. Multiple sclerosis and solar exposure before the age of 15years: case-control study in Cuba, Martinique and Sicily. Mult. Scler. 2010, 16:899-908.
14. Fernandes de Abreu D.A., Ibrahim E.C., Boucraut J., Khrestchatisky M., Feron F. Severity of experimental autoimmune encephalomyelitis is unexpectedly reduced in mice born to vitamin D-deficient mothers. J. Steroid Biochem. Mol. Biol. 2010, 121:250-253.
15. Fernandes de Abreu D.A., Landel V., Feron F. Seasonal, gestational and postnatal influences on multiple sclerosis: the beneficial role of a vitamin D supplementation during early life. J. Neurol. Sci. 2011, 311:64-68.
16. Feron F., Burne T.H., Brown J., Smith E., McGrath J.J., Mackay-Sim A., Eyles D.W. Developmental vitamin D3 deficiency alters the adult rat brain. Brain Res. Bull. 2005, 65:141-148.
17. Forouhi N.G., Luan J., Cooper A., Boucher B.J., Wareham N.J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008, 57:2619-2625.
18. Fugger L., Friese M.A., Bell J.I. From genes to function: the next challenge to understanding multiple sclerosis. Nat. Rev. Immunol. 2009, 9:408-417.
19. Gale C.R., Martyn C.N. Migrant studies in multiple sclerosis. Prog. Neurobiol. 1995, 47:425-448.
20. Gold R., Hartung H.P., Toyka K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 2000, 6:88-91.
21. Handel A.E., Giovannoni G., Ebers G.C., Ramagopalan S.V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 2010, 6:156-166.
22. Handel A.E., Disanto G., Jarvis L., McLaughlin R., Fries A., Ebers G.C., Ramagopalan S.V. Seasonality of admissions with multiple sclerosis in Scotland. Eur. J. Neurol. 2011, 18:1109-1111.
23. Hedstrom A.K., Akerstedt T., Hillert J., Olsson T., Alfredsson L. Shift work at young age is associated with increased risk for multiple sclerosis. Ann. Neurol. 2011, 70:733-741.
24. Hedstrom A.K., Olsson T., Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 2012, 18(9):1334-1336. (Epub 2012 Feb 10. PMID: 22328681). 10.1177/1352458512436596.
25. Hemmer B., Archelos J.J., Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 2002, 3:291-301.
26. Holick M.F. Environmental factors that influence the cutaneous production of vitamin D. Am. J. Clin. Nutr. 1995, 61:638S-645S.
27. Iho S., Takahashi T., Kura F., Sugiyama H., Hoshino T. The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells. J. Immunol. 1986, 136:4427-4431.
28. Islam T., Gauderman W.J., Cozen W., Mack T.M. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69:381-388.
29. Jeffery L.E., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., Walker L.S., Lammas D.A., Raza K., Sansom D.M. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 2009, 183:5458-5467.
30. Joshi S., Pantalena L.C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-Kochan C., Ichiyama K., Yoshimura A., Steinman L., Christakos S., Youssef S. 1,25-Dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell. Biol. 2011, 31:3653-3669.
31. Kampman M.T., Wilsgaard T., Mellgren S.I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 2007, 254:471-477.
32. Kampman M.T., Steffensen L.H., Mellgren S.I., Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult. Scler. 2012, 18(8):1144-1151. (Epub 2012 Feb 21. PMID: 22354743). 10.1177/1352458511434607.
33. Kimball S., Vieth R., Dosch H.M., Bar-Or A., Cheung R., Gagne D., O'Connor P., D'Souza C., Ursell M., Burton J.M. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J. Clin. Endocrinol. Metab. 2011, 96:2826-2834.
34. Lemire J.M., Archer D.C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 1991, 87:1103-1107.
35. Lemire J.M., Adams J.S., Sakai R., Jordan S.C. 1 alpha,25-Dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest. 1984, 74:657-661.
36. Lester G.E., VanderWiel C.J., Gray T.K., Talmage R.V. Vitamin D deficiency in rats with normal serum calcium concentrations. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:4791-4794.
37. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
38. McDowell T.Y., Amr S., Langenberg P., Royal W., Bever C., Culpepper W.J., Bradham D.D. Time of birth, residential solar radiation and age at onset of multiple sclerosis. Neuroepidemiology 2010, 34:238-244.
39. Meehan T.F., DeLuca H.F. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 2002, 408:200-204.
40. Merkler D., Schmelting B., Czeh B., Fuchs E., Stadelmann C., Bruck W. Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult. Scler. 2006, 12:369-374.
41. Mirzaei F., Michels K.B., Munger K., O'Reilly E., Chitnis T., Forman M.R., Giovannucci E., Rosner B., Ascherio A. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann. Neurol. 2011, 70:30-40.
42. Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 2008, 8:685-698.
43. Mowry E.M., Krupp L.B., Milazzo M., Chabas D., Strober J.B., Belman A.L., McDonald J.C., Oksenberg J.R., Bacchetti P., Waubant E. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann. Neurol. 2010, 67:618-624.
44. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
45. Munger K.L., Chitnis T., Frazier A.L., Giovannucci E., Spiegelman D., Ascherio A. Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J. Neurol. 2011, 258:479-485.
46. Nashold F.E., Spach K.M., Spanier J.A., Hayes C.E. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J. Immunol. 2009, 183:3672-3681.
47. Nataf S., Garcion E., Darcy F., Chabannes D., Muller J.Y., Brachet P. 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol. 1996, 55:904-914.
48. Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994, 44:1687-1692.
49. Papeix C., Lubetzki C. If I had a clinically isolated syndrome with MRI diagnostic of MS, I would take vitamin D 10,000IU daily: no. Mult. Scler. 2013, 19:140-142.
50. Pierrot-Deseilligny C., Souberbielle J.C. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?. Brain 2010, 133:1869-1888.
51. Pugliatti M., Sotgiu S., Rosati G. The worldwide prevalence of multiple sclerosis. Clin. Neurol. Neurosurg. 2002, 104:182-191.
52. Rigby W.F., Stacy T., Fanger M.W. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest. 1984, 74:1451-1455.
53. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., Dilthey A., Su Z., Freeman C., Hunt S.E., Edkins S., Gray E., Booth D.R., Potter S.C., Goris A., Band G., Oturai A.B., Strange A., Saarela J., Bellenguez C., Fontaine B., Gillman M., Hemmer B., Gwilliam R., Zipp F., Jayakumar A., Martin R., Leslie S., Hawkins S., Giannoulatou E., D'Alfonso S., Blackburn H., Martinelli Boneschi F., Liddle J., Harbo H.F., Perez M.L., Spurkland A., Waller M.J., Mycko M.P., Ricketts M., Comabella M., Hammond N., Kockum I., McCann O.T., Ban M., Whittaker P., Kemppinen A., Weston P., Hawkins C., Widaa S., Zajicek J., Dronov S., Robertson N., Bumpstead S.J., Barcellos L.F., Ravindrarajah R., Abraham R., Alfredsson L., Ardlie K., Aubin C., Baker A., Baker K., Baranzini S.E., Bergamaschi L., Bergamaschi R., Bernstein A., Berthele A., Boggild M., Bradfield J.P., Brassat D., Broadley S.A., Buck D., Butzkueven H., Capra R., Carroll W.M., Cavalla P., Celius E.G., Cepok S., Chiavacci R., Clerget-Darpoux F., Clysters K., Comi G., Cossburn M., Cournu-Rebeix I., Cox M.B., Cozen W., Cree B.A., Cross A.H., Cusi D., Daly M.J., Davis E., de Bakker P.I., Debouverie M., D'Hooghe M.B., Dixon K., Dobosi R., Dubois B., Ellinghaus D., Elovaara I., Esposito F., Fontenille C., Foote S., Franke A., Galimberti D., Ghezzi A., Glessner J., Gomez R., Gout O., Graham C., Grant S.F., Guerini F.R., Hakonarson H., Hall P., Hamsten A., Hartung H.P., Heard R.N., Heath S., Hobart J., Hoshi M., Infante-Duarte C., Ingram G., Ingram W., Islam T., Jagodic M., Kabesch M., Kermode A.G., Kilpatrick T.J., Kim C., Klopp N., Koivisto K., Larsson M., Lathrop M., Lechner-Scott J.S., Leone M.A., Leppa V., Liljedahl U., Bomfim I.L., Lincoln R.R., Link J., Liu J., Lorentzen A.R., Lupoli S., Macciardi F., Mack T., Marriott M., Martinelli V., Mason D., McCauley J.L., Mentch F., Mero I.L., Mihalova T., Montalban X., Mottershead J., Myhr K.M., Naldi P., Ollier W., Page A., Palotie A., Pelletier J., Piccio L., Pickersgill T., Piehl F., Pobywajlo S., Quach H.L., Ramsay P.P., Reunanen M., Reynolds R., Rioux J.D., Rodegher M., Roesner S., Rubio J.P., Ruckert I.M., Salvetti M., Salvi E., Santaniello A., Schaefer C.A., Schreiber S., Schulze C., Scott R.J., Sellebjerg F., Selmaj K.W., Sexton D., Shen L., Simms-Acuna B., Skidmore S., Sleiman P.M., Smestad C., Sorensen P.S., Sondergaard H.B., Stankovich J., Strange R.C., Sulonen A.M., Sundqvist E., Syvanen A.C., Taddeo F., Taylor B., Blackwell J.M., Tienari P., Bramon E., Tourbah A., Brown M.A., Tronczynska E., Casas J.P., Tubridy N., Corvin A., Vickery J., Jankowski J., Villoslada P., Markus H.S., Wang K., Mathew C.G., Wason J., Palmer C.N., Wichmann H.E., Plomin R., Willoughby E., Rautanen A., Winkelmann J., Wittig M., Trembath R.C., Yaouanq J., Viswanathan A.C., Zhang H., Wood N.W., Zuvich R., Deloukas P., Langford C., Duncanson A., Oksenberg J.R., Pericak-Vance M.A., Haines J.L., Olsson T., Hillert J., Ivinson A.J., De Jager P.L., Peltonen L., Stewart G.J., Hafler D.A., Hauser S.L., McVean G., Donnelly P., Compston A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
54. Simpson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 2011, 82:1132-1141.
55. Sloka S., Silva C., Pryse-Phillips W., Patten S., Metz L., Yong V.W. A quantitative analysis of suspected environmental causes of MS. Can. J. Neurol. Sci. 2011, 38:98-105.
56. Soilu-Hanninen M., Aivo J., Lindstrom B.M., Elovaara I., Sumelahti M.L., Farkkila M., Tienari P., Atula S., Sarasoja T., Herrala L., Keskinarkaus I., Kruger J., Kallio T., Rocca M.A., Filippi M. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83:565-571.
57. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:6030-6037.
58. Storch M.K., Stefferl A., Brehm U., Weissert R., Wallstrom E., Kerschensteiner M., Olsson T., Linington C., Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998, 8:681-694.
59. Thessen Hedreul M., Gillett A., Olsson T., Jagodic M., Harris R.A. Characterization of multiple sclerosis candidate gene expression kinetics in rat experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2009, 210:30-39.
60. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Simmons R., Taylor B.V., Butzkueven H., Kilpatrick T. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003, 327:316.
61. Wang Y., Marling S.J., Zhu J.G., Severson K.S., DeLuca H.F. Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8501-8504.
62. Webb A.R., Kline L., Holick M.F. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab. 1988, 67:373-378.
63. Weissert R., Wallstrom E., Storch M.K., Stefferl A., Lorentzen J., Lassmann H., Linington C., Olsson T. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J. Clin. Invest. 1998, 102:1265-1273.
64. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., Ebers G.C. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005, 330:120.